OBJECTIVE: To report our experience concerning sustained response (SR) after TPO-RA discontinuation in adult pITP patients and to identify possible predictive factors for outcome. METHODS: Thirty-nine pITP patients who received a TPO-RA were evaluated. Response (R) was defined as a platelet count ≥30 × 109 /L and at least a twofold increase in the baseline count and complete response (CR) as a platelet count ≥100 × 109 /L, in the absence of bleeding. Durable response (DR) was defined as a R/CR persisting ≥4 wk with a stable dose of TPO-RA, and SR as the first assessed platelet count ≥30 × 109 /L, available at more than 4 wk after discontinuation of TPO-RA, in the absence of other concomitant or rescue therapies. RESULTS: Twenty-nine/39 (74%) were responders: 18 (46%) reached a CR and 11 (28%) a R. A DR was observed in 16/29 (55%) responders. Seven SR (18%) were reached: five of seven patients achieved a SR from a prior DR. CR was statistically associated with the achievement of a subsequent DR: 13/18 (72%) CR patients obtained a DR, while only three of 11 (27%) R ones did (P = 0.027). CONCLUSIONS: CR was a significant prognostic factor for the achievement of a DR. Moreover, we observed a trend for DR patients to obtain a subsequent SR.
OBJECTIVE: To report our experience concerning sustained response (SR) after TPO-RA discontinuation in adult pITP patients and to identify possible predictive factors for outcome. METHODS: Thirty-nine pITP patients who received a TPO-RA were evaluated. Response (R) was defined as a platelet count ≥30 × 109 /L and at least a twofold increase in the baseline count and complete response (CR) as a platelet count ≥100 × 109 /L, in the absence of bleeding. Durable response (DR) was defined as a R/CR persisting ≥4 wk with a stable dose of TPO-RA, and SR as the first assessed platelet count ≥30 × 109 /L, available at more than 4 wk after discontinuation of TPO-RA, in the absence of other concomitant or rescue therapies. RESULTS: Twenty-nine/39 (74%) were responders: 18 (46%) reached a CR and 11 (28%) a R. A DR was observed in 16/29 (55%) responders. Seven SR (18%) were reached: five of seven patients achieved a SR from a prior DR. CR was statistically associated with the achievement of a subsequent DR: 13/18 (72%) CRpatients obtained a DR, while only three of 11 (27%) R ones did (P = 0.027). CONCLUSIONS:CR was a significant prognostic factor for the achievement of a DR. Moreover, we observed a trend for DR patients to obtain a subsequent SR.
Authors: M Eva Mingot-Castellano; M Teresa Álvarez Román; Luis Fernando Fernández Fuertes; Tomás José González-López; José María Guinea de Castro; Isidro Jarque; M Fernanda López-Fernández; Maria Luisa Lozano; Blanca Sánchez González; David Valcárcel Ferreiras; José Ramón González Porras Journal: Adv Hematol Date: 2019-08-22
Authors: Maria L Lozano; Maria E Mingot-Castellano; María M Perera; Isidro Jarque; Rosa M Campos-Alvarez; Tomás J González-López; Gonzalo Carreño-Tarragona; Nuria Bermejo; Maria F Lopez-Fernandez; Aurora de Andrés; David Valcarcel; Luis F Casado-Montero; Maria T Alvarez-Roman; María I Orts; Silvana Novelli; Nuria Revilla; Jose R González-Porras; Estefanía Bolaños; Manuel A Rodríguez-López; Elisa Orna-Montero; Vicente Vicente Journal: Sci Rep Date: 2019-11-13 Impact factor: 4.379